Liquid Biopsy Market Introduction
Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumour genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.
Liquid Biopsy Market Overview
Increasing importance of non-invasive surgical techniques led to the rapid adoption of liquid biopsy in primary healthcare settings. Liquid biopsy is used for detection of epidermal growth factor receptor mutations and it appears in 10 to 35% of non-small cell lung cancer. Increasing prevalence of non-small cell lung cancer led to the robust growth of the market. According to the American Cancer Society, about 80-85% of lung cancer is non-small cell lung cancer and they are 228,150 newly diagnosed cases of lung cancer in 2019. Further, the rapid advancement of technologies augmented the existing technologies and led to the development of simple equipment. Along with this, increasing R&D investments in strengthening existing portfolios fuelled the growth of the market.
Developing economies like North America and Europe regions accounts more than 60% share of the global market. North America accounts major share in the global market due to high adoption. It is followed by Europe and it is majorly dominated by the UK, Germany, and France. Developing economies like the Asia Pacific and Latin America is the most opportunistic market space for manufacturers due to a limited number of manufacturers in these regions. These regions are expected to witness the highest growth rate during the forecast period. Rest of world accounts small fraction in the global market and it has the limited presence of manufacturers
Liquid Biopsy market players include Biocept, Inc., Qiagen Corporation, Roche Diagnostics, RainDance Technologies, Trovagene, Genomic Health, CellMax Life and others
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=203&page=requestsample
Liquid Biopsy Market Segmentation
By Biomarker Type
+ ctDNA
+ Exosomes
+ CTC cells
By End User
+ Hospitals
+ Cancer Research Centres
+ Diagnostic Laboratories
By Region
+ North America
+ Latin America
+ Europe
+ Asia Pacific
+ Rest of the World
Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=203&page=askfordiscount

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
FutureWise Key Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global Liquid Biopsy Market by Biomarker Type, by End-User, and by Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Table of Contents
• Introduction
o Scope and Objective
o Assumptions and Acronyms
o Forecast Factors
o Research Methodology
• Executive Summary
o Industry Cluster Analysis
o Competition Matrix
o Strategies Recommendations
• Market Definition
o Report Scope (Inclusions & Exclusions)
o Market Segmentation
• Global Liquid Biopsy Market Overview
o Global Liquid Biopsy Market Revenue (USD Mn)
• Key Inclusions
o Porter’s Five Force analysis
o Market Dynamics
o Industry Trends
o Regulatory Guidelines
o Opportunities in Liquid Biopsy
• Competition Dynamics
o Company Share Analysis (2019)
o Top 10 Product Pricing by Region
• Global Liquid Biopsy Market Revenue (USD Mn), 2019-2026 by Biomarker Type
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
• Global Liquid Biopsy Market Revenue (USD Mn), 2019-2026 by End User
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
 Diagnostic Laboratories
• Global Liquid Biopsy Market Revenue (USD Mn), 2019-2026 by Region
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Region,2026
 North America
 Latin America
 Europe
 Asia Pacific
 Rest of world
• North America Liquid Biopsy Market Revenue (US$ Mn), 2019-2026
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2026
 US
 Canada
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
 Diagnostic Laboratories
• Latin America Liquid Biopsy Market Revenue (US$ Mn), 2019-2026
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2026
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
 Diagnostic Laboratories
• Europe America Liquid Biopsy Market Revenue (US$ Mn), 2019-2026
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2026
 Germany
 France
 Spain
 UK
 Russia
 Poland
 Rest of Europe
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
 Diagnostic Laboratories
• Asia Pacific America Liquid Biopsy Market Revenue (US$ Mn), 2019-2026
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2026
 Emerging Asia
• China
• India
• ASEAN-5
• Rest of Emerging Asia
 Japan
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
 Diagnostic Laboratories
• Rest of World America Liquid Biopsy Market Revenue (US$ Mn), 2019-2026
o Key Market Findings
o Long Term ROI Segments
o Revenue Opportunity Influencing Factors
o Market Revenue (USD Mn) Assessment and Forecast by Country, 2019-2026
 Middle East
 South Africa
 North Africa
 Rest of World
o Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 2019-2026
 ctDNA
 Exosomes
 CTC cells
o Market Revenue (USD Mn) Assessment and Forecast by End User, 2019-2026
 Hospitals
 Cancer Research Centres
• Diagnostic Laboratories
• Company Profiles
o Competition Landscape
o Global Company Share (USD Mn) Overview, 2019
o Company Profiles
 Biocept, Inc.
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 Qiagen Corporation
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 Roche Diagnostics
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 RainDance Technologies
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 Trovagene
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 Genomic Health
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
 CellMax Life
• Corporate Overview
• Financial Performance
• Peer Comparison & 3C marketing equation
• Company Strategy & Channel Management
• Research Sources & Primary Verbatim

Inquire further details about this report at: [email protected]

About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.

Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com